Elevance Health, Inc. (ELV)

Blueprint Medicines Stock Forecast

Stock Price Forecast

The 14 analysts that cover Blueprint Medicines stock have a consensus rating of "Buy" and an average price target of $416.86, which forecasts a 51.62% increase in the stock price over the next year. The lowest target is $297 and the highest is $615.

Price Target: $416.86 (+51.62%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$297	$416.86	$435	$615
Change	+8.03%	+51.62%	+58.22%	+123.69%

Analyst Ratings

The average analyst rating for Blueprint Medicines stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	4	5	5	5	5	4
Buy	9	9	8	8	7	8
Hold	2	1	2	2	2	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	15	15	15	14	15

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Michael Ha Baird	Baird	Hold Maintains $492 → $297	Hold	Maintains	$492 → $297	+8.03%	Jul 25, 2025
Lisa Gill JP Morgan	JP Morgan	Buy Maintains $472 → $384	Buy	Maintains	$472 → $384	+39.67%	Jul 22, 2025
Andrew Mok Barclays	Barclays	Buy Maintains $358 → $327	Buy	Maintains	$358 → $327	+18.94%	Jul 22, 2025
David Toung Argus Research	Argus Research	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Jul 21, 2025
A.J. Rice UBS	UBS	Strong Buy Maintains $484 → $435	Strong Buy	Maintains	$484 → $435	+58.22%	Jul 18, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

198.61B

Increased by 12.33%

from 176.81B

Revenue Next Year

210.05B

Increased by 5.76%

from 198.61B

EPS This Year

34.75

Increased by 35.31%

from 25.68

EPS Next Year

39.69

Increased by 14.22%

from 34.75

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	121.87B	138.64B	156.60B	171.34B	176.81B	198.61B	210.05B	223.30B
Revenue Growth	16.94%	13.77%	12.95%	9.41%	3.19%	12.33%	5.76%	6.31%
EPS	17.98	24.95	24.28	25.22	25.68	34.75	39.69	45.84
EPS Growth	-2.65%	38.77%	-2.69%	3.87%	1.82%	35.31%	14.22%	15.50%
Forward PE	-	-	-	-	-	7.91	6.93	6.00
No. Analysts	-	-	-	-	-	25	24	12

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	209.0B	223.6B	238.6B
Avg	198.6B	210.0B	223.3B
Low	191.1B	196.5B	213.2B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	18.2%	12.6%	13.6%
Avg	12.3%	5.8%	6.3%
Low	8.1%	-1.0%	1.5%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	36.33	43.68	50.74
Avg	34.75	39.69	45.84
Low	33.09	37.61	42.39

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	41.5%	25.7%	27.8%
Avg	35.3%	14.2%	15.5%
Low	28.9%	8.2%	6.8%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.